Federal Register: January 4, 2005 (Volume 70, Number 2)
DOCID: FR Doc 05-77
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
NOTICE: NOTICES
ACTION: Applications, hearings, determinations, etc.:
SUBJECT CATEGORY:
Manufacturer of Controlled Substances; Notice of Application
DOCUMENT SUMMARY:
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 1, 2004, Houba, Inc.,
PO Box 190, 16235 State Road 17, Culver, Indiana 46511, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in Schedule II; and by letter dated October 1, 2004,
to modify its name to Acura Pharmaceutical Technologies, Inc., and change the address by removing the P.O. Box 190.
Drug Schedule Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representative,
Office of Liaison and Policy (ODLR) and must be filed no later than March 7, 2005.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 0577 Filed 1305; 8:45 am]
BILLING CODE 441009P
SUMMARY:
Houba, Inc.,
DOCUMENT BODY 2:
Pursuant to Section 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on October 1, 2004, Houba, Inc.,
PO Box 190, 16235 State Road 17, Culver, Indiana 46511, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in Schedule II; and by letter dated October 1, 2004,
to modify its name to Acura Pharmaceutical Technologies, Inc., and change the address by removing the P.O. Box 190.
Drug Schedule Oxycodone (9143)........................... II
Hydrocodone (9193)......................... II
The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.
Any other such applicant and any person who is presently registered with DEA to manufacture such substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such comments or objections may be addressed, in quintuplicate,
to the Deputy Assistant Administrator, Office of Diversion Control,
Drug Enforcement Administration, United States Department of Justice,
Washington, DC 20537, Attention: DEA Federal Register Representative,
Office of Liaison and Policy (ODLR) and must be filed no later than March 7, 2005.
Dated: December 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.
[FR Doc. 0577 Filed 1305; 8:45 am]
BILLING CODE 441009P